CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 66 enrolled
Drug / intervention
Light Adjustable lens (LAL) and Light Delivery Device (LDD)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03895034
NCT03895034N/ACompleted
CompareCT.gov

A Single Center Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes

RxSight, Inc.·interventional·Posted Mar 29, 2019·Updated May 12, 2022

In Brief

A clinical study evaluating Light Adjustable lens (LAL) and Light Delivery Device (LDD) for Aphakia and Cataract. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The objective of this study is to evaluate, for the visual correction of aphakia, whether the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) can be used to improve visual outcomes after performing adjustments of the LAL with the LDD. This is an exploratory study. No primary effectiveness endpoints will be identified.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAphakia, Cataract
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMar 29, 2019
Enrollment StartJun 14, 2018
Primary CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.3 years ago

Interventions

Light Adjustable lens (LAL) and Light Delivery Device (LDD)device

Eligible eyes will receive Light adjustable lens with Light delivery Device treatments